Đang chuẩn bị liên kết để tải về tài liệu:
Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
The enhanced knowledge of cancer biology has led to considerable advancement in systemic therapy for advanced breast cancer. Recently, studies showed that cyclin-dependent kinase (CDK) 4/6 inhibitor, when added to endocrine therapy, had improved the outcomes of patients with advanced ER-positive HER2- negative breast cancer. |